Novavax (MEX:NVAX) Change In Payables And Accrued Expense : MXN-6,483 Mil (TTM As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Novavax Change In Payables And Accrued Expense?

Novavax's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was MXN-4,334 Mil. It means Novavax's Accounts Payable & Accrued Expense declined by MXN4,334 Mil from Dec. 2024 to Mar. 2025 .

Novavax's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was MXN-8,043 Mil. It means Novavax's Accounts Payable & Accrued Expense declined by MXN8,043 Mil from Dec. 2023 to Dec. 2024 .

Novavax Change In Payables And Accrued Expense Historical Data

The historical data trend for Novavax's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Change In Payables And Accrued Expense Chart

Novavax Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

3,245.60

12,315.09

17,807.63

-6,429.93

-8,042.50

Novavax Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-4,521.83	-1,722.51	459.30	-885.70	-4,333.99

Novavax Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-6,483 Mil.

Novavax Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Novavax's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (MEX:NVAX) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

NVAX:USA NVV1:Germany NVV1:Germany NVV1:Germany NVV1:Bulgaria NVAX:Austria

Address

700 Quince Orchard Road, Gaithersburg, MD, USA, 20878

Website

https://www.novavax.com

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.